The Cutaneous Lupus Disease Activity and Severity Index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al

Por Krathen, Michael, Albrecht, Joerg, Werth, Victoria P.
Publicado em 2008

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52 week trial

Por Okon, Lauren, Rosenbach, Misha, Krathen, Michael, Rose, Mathew, Propert, Kathleen, Okawa, Joyce, Werth, Victoria
Publicado no J Am Acad Dermatol (2014)

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project...

Por Kim, Youn H., Tavallaee, Mahkam, Sundram, Uma, Salva, Katrin A., Wood, Gary S., Li, Shufeng, Rozati, Sima, Nagpal, Seema, Krathen, Michael, Reddy, Sunil, Hoppe, Richard T., Nguyen-Lin, Annie, Weng, Wen-Kai, Armstrong, Randall, Pulitzer, Melissa, Advani, Ranjana H., Horwitz, Steven M.
Publicado no J Clin Oncol (2015)